Baxter International (BAX) Hisse Özeti
Baxter International Inc. iştirakleri aracılığıyla Amerika Birleşik Devletleri'nde bir sağlık ürünleri portföyü sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
BAX Community Fair Values
Create NarrativeSee what 38 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Baxter International Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$26.34 |
| 52 Haftanın En Yüksek Seviyesi | US$30.00 |
| 52 Haftanın En Düşük Seviyesi | US$15.73 |
| Beta | 0.60 |
| 1 Aylık Değişim | 21.16% |
| 3 Aylık Değişim | 37.33% |
| 1 Yıllık Değişim | 7.34% |
| 3 Yıllık Değişim | -36.58% |
| 5 Yıllık Değişim | -64.39% |
| Halka arzdan bu yana değişim | 1,912.85% |
Son Haberler & Güncellemeler
Recent updates
Anlatı Güncellemesi • Aug 15
BAX: Q2 Execution And Cash Tender Offers Will Shape Margin Narrative
Analysts have lifted the Baxter International fair value estimate from about $27.29 to roughly $28.73, reflecting higher price targets in the $24 to $29 range, along with updated views on earnings potential, recent segment performance, and the outlook for margins and P/E multiples. Analyst Commentary Street research on Baxter International has turned more balanced, with several firms lifting price targets into the mid to high US$20s and a cluster of ratings moving toward Neutral or Hold.Seeking Alpha • Aug 03
Baxter International: The Gains Can Continue, But Should Slow
Summary Baxter International has shown early signs of a turnaround, with improving execution and raised revenue guidance supporting cautious optimism. BAX's valuation has expanded from distressed levels, now trading at ~13x earnings and ~9.5x EV/EBITDA, yet remains attractive if growth continues. Management's focus on operational improvements, cost savings, and a conservative outlook suggests potential for further upside if EPS growth materializes. Risks remain around execution, leverage, and business headwinds, but deleveraging and possible multiple expansion offer a still-compelling, though less asymmetric, risk/reward. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jul 31
BAX: Q2 Execution And Segment Mix Will Test Emerging Margin Recovery Narrative
The analyst price target for Baxter International is now set around $27, up from about $22, as analysts point to improved earnings expectations and healthier sales momentum following recent results and model updates. Analyst Commentary Recent research on Baxter International shows a cluster of price target increases and rating changes that focus squarely on earnings execution, segment performance and medium term growth visibility.
Anlatı Güncellemesi • Jul 16
BAX: Segment Realignment And Margin Execution Will Drive Future Repricing Potential
The analyst fair value estimate for Baxter International has risen from $33.29 to $34.14. This change reflects a combination of recent price target increases from firms such as Goldman Sachs and Evercore ISI and more cautious views that highlight mixed sentiment around the stock.Analiz Makalesi • Jun 21
Baxter International (BAX) Stock Could Be 7.7% Undervalued After MediThinQ Distribution Deal
Synovis Micro Companies Alliance, a subsidiary of Baxter International (BAX), has signed an exclusive multi-year deal with MediThinQ to distribute the SHIYA 3D surgical visualization platform globally, expanding Baxter’s footprint in digital surgical technology. See our latest analysis for Baxter International. The MediThinQ agreement arrives after a volatile stretch for Baxter International, with a 19.75% 90 day share price return contrasting with a 33.11% decline in 1 year total shareholder...
Anlatı Güncellemesi • Jun 14
BAX: Back Half Execution And CFO Uncertainty Will Drive A Bearish Outlook
The analyst price target for Baxter International has shifted modestly lower to $17.00 from $18.00, as analysts factor in expectations for a year weighted more toward the second half, leadership uncertainty surrounding the CFO search, and relatively more appealing valuations in other medical technology stocks. Analyst Commentary Recent research on Baxter International has turned more cautious, with several bearish analysts revisiting their ratings and price targets in light of company specific and sector wide factors.Anlatı Güncellemesi • May 31
BAX: Back Half Execution Will Shape Margin Recovery And Rerating Potential
Analysts have trimmed their overall price expectations for Baxter International, with the updated fair value estimate easing slightly to about $21.54 from $21.63. Recent target cuts, including Citi's move to $17 and other adjustments across the Street, reflect concerns around a back-half weighted year, the ongoing CFO search, and revised assumptions for profit margins and future P/E multiples.Anlatı Güncellemesi • May 14
BAX: Mixed Price Signals And Margin Pressures Will Shape A Cautious Fair Outlook
Analysts now place Baxter International's fair value at $18.00, up from $17.00, reflecting updated assumptions for discount rate, growth, margins, and expected future P/E after a mix of recent price target cuts and a more recent $2 increase from the Street. Analyst Commentary Recent research has been mixed, with several bearish analysts trimming price targets over the past few months even as one bank lifted its target by US$2.Anlatı Güncellemesi • Apr 29
BAX: 2026 Margin Execution And Cost Clarity Will Drive Repricing Potential
Narrative Update The analyst price target for Baxter International has been trimmed by $0.09 as analysts factor in recent sector wide target cuts and concerns about margin pressures and limited near term visibility following the company's 2026 outlook. Analyst Commentary Recent research coverage on Baxter International has centered on margin headwinds, higher non operating items, and an outlook that many see as underwhelming, particularly into 2026.Anlatı Güncellemesi • Apr 14
BAX: Margin Pressures And Execution Risks Will Shape A More Balanced Outlook
Analyst fair value for Baxter International has been reset from $15.00 to $17.00 as analysts factor in updated revenue growth, margin assumptions, and sector level price target cuts across recent research notes. Analyst Commentary Recent research has centered on resetting expectations for Baxter International, with bearish analysts trimming price targets and highlighting execution and earnings risk tied to the latest guidance.Anlatı Güncellemesi • Mar 31
BAX: 2026 Execution And Margin Visibility Will Determine Potential Upside Repricing
Analysts have edged Baxter International's fair value estimate higher to about $33.38 from $32.59, even as several firms recently reduced their price targets to a range of $17 to $30 after underwhelming 2026 guidance and margin pressures. Analyst Commentary Recent Street research has centered on Baxter's 2026 outlook, with several firms trimming price targets after guidance and margin commentary fell short of earlier expectations.Anlatı Güncellemesi • Mar 16
BAX: Future Margin Stability And 2026 Outlook Could Unlock Upside Potential
Analysts have trimmed Baxter International's fair value estimate from $43.95 to $32.59, citing lower price targets in the $17 to $30 range and updated assumptions for slower revenue growth, slimmer margins, a higher discount rate, and a richer future P/E multiple. Analyst Commentary Recent Street research on Baxter reflects a cautious tone overall, but there are still pockets of constructive commentary that matter if you are weighing the new fair value estimate against external views.Anlatı Güncellemesi • Mar 02
BAX: Q4 Reset And 2026 Outlook Will Test Margin Recovery Hopes
Analysts have trimmed their average 12 month price target for Baxter International by several dollars into the high teens, pointing to weaker than expected 2026 margin guidance and limited near term visibility as key drivers of the reset. Analyst Commentary Recent research shows a clear reset in expectations for Baxter International, with most firms trimming price targets and highlighting weaker 2026 guidance as a key catalyst.Anlatı Güncellemesi • Feb 16
BAX: Q4 Results And 2026 Outlook Will Clarify Fairly Balanced Risks
The updated analyst price target for Baxter International has decreased by about $1.50, as analysts cite limited visibility around the company’s 2026 outlook while still accounting for modest adjustments to growth, margins, and future P/E expectations. Analyst Commentary Recent research updates show a mix of caution and selective optimism around Baxter International, with several firms revising price targets and reassessing how much uncertainty is already reflected in the shares.Anlatı Güncellemesi • Feb 02
BAX: Q4 Results And 2026 Outlook Will Resolve Discounted Uncertainty
Analysts have made only minor tweaks to their modeled discount rate, revenue growth, profit margin, and future P/E for Baxter International, resulting in a relatively stable fair value estimate around $23.13. In contrast, Street price targets have shifted modestly, with one firm trimming its view to $30 and another nudging its target to $23 as they factor in current uncertainty and the potential clarity from upcoming results and the 2026 outlook.Anlatı Güncellemesi • Jan 19
BAX: Q4 And 2026 Outlook Will Reduce Uncertainty And Support Margin Recovery
Narrative Update: Baxter International Analyst Price Target Shift Analysts have modestly reduced their blended price target on Baxter International, with updated modeling pointing to a fair value trim of about US$0.67 per share to US$23.13, as they factor in lower future P/E assumptions and recent guidance cuts, partly balanced by slightly firmer revenue growth expectations. Analyst Commentary Recent research shows a clear split between bullish analysts, who see current uncertainty as already reflected in the share price, and bearish analysts, who focus on execution risk and softer guidance.Anlatı Güncellemesi • Jan 05
BAX: Earnings Headwinds And Margin Pressure Will Drive A Lower Share Repricing
Analysts have reduced their fair value estimate for Baxter International from about US$19.00 to about US$15.00 per share, reflecting lower price targets of US$22.00 (previously US$25.00) and more modest expectations for growth and margins following recent results and guidance cuts. Analyst Commentary Bearish analysts are resetting expectations on Baxter International after recent quarterly results and guidance cuts, pointing to weaker execution and softer growth than previously anticipated.Anlatı Güncellemesi • Dec 15
BAX: Margin Recovery Will Follow New Leadership And Cost Discipline Over Time
Analysts have trimmed their fair value estimate for Baxter International slightly, from approximately $24.07 to $23.80 per share, reflecting reduced price targets to around $22 in light of softer sales, margin pressure, and lowered guidance that signal ongoing near term earnings headwinds. Analyst Commentary Analyst sentiment around Baxter International remains mixed, with recent earnings results and guidance prompting a more cautious stance on the stock despite its reduced valuation.Anlatı Güncellemesi • Dec 01
BAX: Margin Recovery Will Follow New CEO’s Drive for Operational Efficiency
Analysts have lowered their price target for Baxter International from $25 to $22. They cite weaker-than-expected sales, margin pressures, continued business headwinds, and reduced forward guidance as key factors behind the adjustment.Anlatı Güncellemesi • Nov 17
BAX: Margin Headwinds Will Ease With New CEO and Business Resilience
Analysts have lowered their price target for Baxter International from $25 to $22 per share. They cite disappointing recent sales performance and ongoing margin pressures that are expected to persist into 2026.Anlatı Güncellemesi • Nov 03
BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026
Analysts have reduced their price target for Baxter International from approximately $28 to $24.07 per share. They cite persistent revenue headwinds, lower margins, and management's more cautious outlook for 2025 and beyond.Anlatı Güncellemesi • Oct 20
Hospital Normalization And Demographic Trends Will Support Connected Healthcare
Baxter International’s analyst price target has been lowered from approximately $29.47 to $28.00. Analysts cite slower-than-expected progress in margin expansion and revenue growth following disappointing earnings and reduced guidance.Anlatı Güncellemesi • Oct 05
Hospital Normalization And Demographic Trends Will Support Connected Healthcare
Analysts have lowered their price targets for Baxter International to $25 from previous levels above $36, citing concerns about slower than expected margin expansion, delayed sales growth recovery, and business challenges highlighted in recent guidance cuts. Analyst Commentary Recent analyst reports have provided a mixed outlook for Baxter International, highlighting both challenges and potential positives as the company navigates through a period of transition and recovery.Anlatı Güncellemesi • Sep 05
Hospital Normalization And Demographic Trends Will Support Connected Healthcare
Baxter International's consensus price target was slightly reduced to $29.00, as disappointing Q2 results, lowered full-year guidance, and a slower-than-expected path to sales and margin improvement undermined near-term growth confidence. Analyst Commentary Disappointing Q2 performance and reduced full-year guidance undermined near-term confidence in Baxter's growth trajectory.Seeking Alpha • Apr 21
Baxter: Messy, Yet Appealing, If New Management Can Deliver
Summary Baxter's sale of its kidney business, Vantive, was executed at a low price, raising concerns about its ability to effectively deleverage its balance sheet. Despite the sale, Baxter's net debt remains high, and adjusted earnings are under pressure, with a significant reduction in the dividend indicating anticipated earnings challenges. The company's leadership change and modest organic growth provide some hope, but the highly adjusted earnings and mixed track record create an opaque investment outlook. Shares appear reasonably priced, but the situation remains fluid and uncertain, making it difficult to have strong conviction about improved shareholder outcomes. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Baxter International: An Uncompelling Investment With High Debt
Summary Recent capital allocation decisions have been questionable. The stock doesn't really seem to fit compellingly within a portfolio constructed along the lines of any popular investment approaches. Baxter International seems pretty uncompelling as an investment opportunity, and investors should look elsewhere. Read the full article on Seeking AlphaHissedar Getirileri
| BAX | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -1.5% | 0.4% | -1.5% |
| 1Y | 7.3% | -12.6% | 17.9% |
Getiri vs. Endüstri: BAX geçen yıl % -12.6 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: BAX geçen yıl % 17.9 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| BAX volatility | |
|---|---|
| BAX Average Weekly Movement | 6.0% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: BAX son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: BAX 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1931 | 37,500 | Andrew Hider | www.baxter.com |
Baxter International Inc. iştirakleri aracılığıyla Amerika Birleşik Devletleri'nde bir sağlık ürünleri portföyü sunmaktadır. Şirket üç segmentte faaliyet göstermektedir: Tıbbi Ürünler ve Tedaviler, Sağlık Sistemleri ve Teknolojileri ve İlaçlar. Steril intravenöz (IV) solüsyonlar; infüzyon sistemleri ve cihazları; parenteral beslenme tedavileri; inhale anestezikler; jenerik enjekte edilebilir farmasötikler; cerrahi hemostat ve sızdırmazlık ürünleri; gelişmiş cerrahi ekipmanlar; akıllı yatak sistemleri; hasta izleme ve teşhis teknolojileri ve solunum sağlığı cihazlarının yanı sıra ameliyathane entegrasyon teknolojileri, hassas konumlandırma cihazları ve diğer aksesuarları içeren cerrahi alan için gelişmiş ekipmanlar sunmaktadır.
Baxter International Inc. Temel Bilgiler Özeti
| BAX temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$13.65b |
| Kazançlar(TTM) | -US$968.00m |
| Gelir(TTM) | US$11.47b |
1.2x
P/S Oranı-14.1x
F/K OranıBAX aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| BAX gelir tablosu (TTM) | |
|---|---|
| Gelir | US$11.47b |
| Gelir Maliyeti | US$7.56b |
| Brüt Kâr | US$3.91b |
| Diğer Giderler | US$4.88b |
| Kazançlar | -US$968.00m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.87 |
| Brüt Marj | 34.10% |
| Net Kâr Marjı | -8.44% |
| Borç/Özkaynak Oranı | 153.1% |
BAX uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
0.2%
Mevcut Temettü Verimi-11%
Ödeme OranıBAX güvenilir bir temettü ödüyor mu?
BAX temettü geçmişine ve kıyaslamalara bakın| Baxter International temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Aug 28 2026 |
| Temettü Ödeme Tarihi | Oct 01 2026 |
| Eski temettüye kadar geçen günler | 5 days |
| Temettü ödeme tarihine kadar geçen günler | 39 days |
BAX güvenilir bir temettü ödüyor mu?
BAX temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/21 17:04 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Baxter International Inc. 34 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Matthew Taylor | Barclays |
| Matthew Miksic | Barclays |